CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the appointment of Biren Amin, M.B.A., as Chief Financial Officer. Mr. Amin comes to Immuneering from Jefferies Financial…
Read More
In this article by Gail Dutton, our co-founder and CEO Ben Zeskind discusses Immuneering’s proprietary Disease Cancelling Technology platform, and our growing pipeline of medicines targeting signaling pathways that are…
In this article by Allie Nawrat, our co-founder and CEO Ben Zeskind discusses Immuneering’s recent financing of $62m, in an oversubscribed Series B round led by high-profile life science investors….
In this article by Michael Fitzhugh, Immuneering co-founder and CEO Ben Zeskind discusses the company’s recent oversubscribed Series B financing, which raised a total of $62M to advance its Disease…
Financing to support advancement of Immuneering’s lead drug programs targeting cancers driven by alterations in the RAS/MAPK pathway and pipeline development of earlier programs in neuroscience and immuno-oncology.
In this Genetic Engineering & Biotechnology News article by Richard A. Stein, Immuneering’s Head of Neuroscience J.L. Ross, Ph.D. discusses the company’s integration of biomarkers with bioinformatic, proteomic, and gene signature information…
In this article by Zach Winn, Immuneering co-founder and CEO Ben Zeskind discusses his journey from MIT undergraduate to biotech entrepreneur. He speaks to the company’s decade-plus of experience helping…
Breakthroughs in artificial intelligence (AI) hold enormous potential as it can automate complex tasks and go even beyond human performance. In their study, McKinney et al.1 showed the high potential…
Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials. A PubMed search identified 119…
pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that encodes a polyglutamine (polyQ) tract in the huntingtin (HTT) gene.
